-
Options Brief: Celsion Corporation
Friday, May 27, 2011 - 10:16am | 75Shares of Celsion Corporation (NASDAQ: CLSN) are higher on the session by 1.64%, trading at $9.94. Overall call volume is now running at 11.59x the daily average, with 16% of all calls traded being purchases on the offer. 1,727 contracts have traded on the session so far. Celsion Corporation is...
-
UPDATE: J.P. Morgan Raises PT on Emergent BioSolutions to $35
Friday, May 27, 2011 - 8:02am | 149J.P. Morgan is out with its report today on Emergent BioSolutions (NYSE: EBS), raising its PT from $27 to $35. In a note to clients, J.P. Morgan writes, "We are updating our estimates, raising our Dec 11 PT (to $35 from $27), and reiterating our OW rating on EBS following today's news that the US...
-
Celsion Corporation Announces $8.6M Equity Offering of Common Stock and Warrants
Friday, May 27, 2011 - 8:01am | 183Celsion Corporation (NASDAQ: CLSN) today announced that it has entered into a definitive securities purchase agreement with institutional investors, as well as certain officers and directors of the Company, for the issuance and sale in a private placement transaction of 3,218,612 shares of common...
-
Global Hunter Initiates Cubist Pharmaceuticals At Neutral
Friday, May 27, 2011 - 7:34am | 27Global Hunter Securities has initiated coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with a Neutral rating and no price target.
-
Global Hunter Initiates Pharmacyclics At Buy, $13 PT
Friday, May 27, 2011 - 7:33am | 25Global Hunter Securities has initiated coverage on Pharmacyclics (NASDAQ: PCYC) with a Buy rating and $13 price target.
-
JP Morgan Raises PT On Emergent BioSolutions To $35
Friday, May 27, 2011 - 7:00am | 27JP Morgan has raised the price target on Emergent BioSolutions (NYSE: EBS) from $27 to $35 and maintains its Overweight rating.
-
Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA Accepted for Review by European Medicines Agency
Thursday, May 26, 2011 - 1:01pm | 106Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Marketing Authorization Application, filed by its wholly owned subsidiary, Savient Pharma Ireland Limited, seeking approval of KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy, has...
-
Calls Purchased on Rigel Pharmaceuticals
Thursday, May 26, 2011 - 11:31am | 129Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) are lower on the session by 2.83%, currently trading at $8.25. The stock has been moving largely higher over the past three months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying calls on the name...
-
Options Brief: Arena Pharmaceuticals, Inc.
Thursday, May 26, 2011 - 10:21am | 86Shares of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) are higher on the session by 11.59%, trading at $1.54. Overall call volume is now running at 3.57x the daily average, with 50% of all calls traded being purchases on the offer. 2,778 contracts have traded on the session so far. Arena...
-
NASDAQ Stocks Hitting 52-Week Highs
Thursday, May 26, 2011 - 10:09am | 146Cubist Pharmaceuticals Inc (NASDAQ: CBST) shares gained 5.33% to create a new 52-week high of $38.72. CBST's trailing-twelve-month operating margin is 31.02%. HealthStream Inc (NASDAQ: HSTM) shares jumped 4.18% to create a new 52-week high of $13.20. HSTM shares have surged 176.64% over the past...
-
Morning Market Movers
Thursday, May 26, 2011 - 9:55am | 133Clean Diesel Technologies Inc (NASDAQ: CDTI) shares advanced 53.85% to $6.00 at 9:50 am. CDTI's Heavy Duty Diesel Systems division received around $2.0 million in orders for its verified (approved) emission reduction products. Xinyuan Real Estate Co Ltd (NYSE: XIN) climbed 15.63% to $2.22. XIN...
-
UPDATE: Global Hunter Initiates ArQule at Accumulate
Thursday, May 26, 2011 - 9:42am | 200Global Hunter is out with its report today on ArQule (NASDAQ: ARQL), initiating ARQL at Accumulate. In a note to clients, Global Hunter writes, "We are initiating coverage of ARQL with an Accumulate rating and $11 price target. ARQL is focused on the development of small molecule drugs for cancer...
-
CEL-SCI Corporation Study Shows LEAPS Dendritic Cell Therapy to Be Effective in Treating H1N1 Virus
Thursday, May 26, 2011 - 9:15am | 117CEL-SCI Corporation (NYSE: CVM) today announced the positive results of efficacy studies in mice of L.E.A.P.S.TM H1N1 activated dendritic cells to treat the H1N1 virus. Scientists found that H1N1-infected mice treated with LEAPS-H1N1 DCs showed a survival advantage over mice treated with control...
-
Rigel Announces Prices Public Offering of 16.3M Shares at $8.00 per Share
Thursday, May 26, 2011 - 9:02am | 123Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the pricing of its previously announced underwritten public offering of 16,300,000 shares of its common stock, offered at a price of $8.00 per share to the public. The gross proceeds to Rigel from this offering are expected to be...
-
Benzinga's Top Pre-Market NASDAQ Losers
Thursday, May 26, 2011 - 8:23am | 156Rigel Pharmaceuticals Inc (NASDAQ: RIGL) dipped 5.77% to $8 in the pre-market session. RIGL reported that it intends to offer and sell shares of its common stock in an underwritten public offering. Complete Genomics Inc (NASDAQ: GNOM) dropped 1.65% to $13.10 in the pre-market trading. GNOM priced...